<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        247-212-08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PAROXAT 20 MG F-C TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PAROXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Paroxat is one of a type of antidepressants known as Selective Serotonin Re-uptake Inhibitors (SSRIs). Low levels of the hormone serotonin are thought to be a cause of depression and other related conditions. Paroxat works by bringing the levels of serotonin back to normal. Paroxat is used in adults to treat:</p><ul><li>Depression,</li><li>Obsessive compulsive disorder,</li><li>Panic disorder with or without agoraphobia (fear of open spaces or new situations),</li><li>Social anxiety disorders/social phobias,</li><li>Post traumatic stress disorder,</li><li>Anxiety disorders.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Paroxat tablets and tell your doctor&nbsp;if you are:</strong></p><ul><li>Allergic&nbsp;(hypersensitive) to paroxetine or any of the other ingredients (see section 6),</li><li>Taking medicines called&nbsp;pimozide&nbsp;or&nbsp;monoamine oxidase inhibitors&nbsp;(MAOls, including moclobemide), or have taken them at any time within the last two weeks,</li><li>Taking a&nbsp;tranquilliser called thioridazine or pimozide.</li></ul><p>&nbsp;</p><ul><li>Using medicines containing linezolid, which is used for the treatment of infections.</li></ul><p>Check with your doctor or pharmacist before taking Paroxat tablets&nbsp;if you:</p><ul><li>Suffer from&nbsp;eye, kidney, liver&nbsp;or&nbsp;heart&nbsp;problems,</li><li>Suffer from&nbsp;epilepsy&nbsp;or have a&nbsp;history of fits,</li><li>Have episodes of&nbsp;mania&nbsp;(overactive behaviour or thoughts),</li><li>Are having electro-convulsive therapy&nbsp;(ECT),</li><li>Have a&nbsp;history of bleeding disorders,</li><li>Suffer from&nbsp;diabetes,</li><li>Are on a&nbsp;low sodium diet,</li><li>Have&nbsp;glaucoma&nbsp;(pressure in the eye).</li></ul><p><strong>Take special care with Paroxat</strong></p><ul><li>Contact your doctor if you develop symptoms such as confusion, restlessness, sweating, shaking, shivering, hallucinations (strange visions or sounds), sudden jerks of the muscles or a fast heartbeat, since these symptoms could be a sign of &ldquo;serotonin syndrome&rdquo;.</li><li>SSRIs/SNRIs may increase the risk of postpartum hemorrhage.</li></ul><p><strong>Thoughts of suicide and worsening of your depression or anxiety disorder</strong></p><p>If you are depressed and/or have anxiety disorders, you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines take time to work, (usually about two weeks but sometimes longer).</p><p>You may be more likely to think like this if you:</p><ul><li>Have previously had thoughts about killing or harming yourself.</li><li>Are a young adult. Information from clinical trials has shown an increased risk of suicidal behavior in young adults (less than 25 years old) with psychiatric conditions who were treated with an antidepressant.</li></ul><p>If you have thoughts of harming or killing yourself at any time,&nbsp;contact your doctor or go to a hospital straight away.</p><p><strong>Children and adolescents under 18</strong></p><p>Paroxat should not be used for children and adolescents under 18 years. Also, patients under 18 have an increased risk of side effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behavior and anger) when they take Paroxat. If your doctor has prescribed Paroxat for you (or your child) and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when you (or your child) are taking Paroxat. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of Paroxat in this age group have not yet been demonstrated. In studies of Paroxat in under 18s, common side effects that affected less than 1 in 10 children/adolescents were: an increase in suicidal thoughts and suicide attempts, deliberately harming themselves, being hostile, aggressive or unfriendly, lack of appetite, shaking, abnormal sweating, hyperactivity (having too much energy), agitation, changing emotions (including crying and changes in mood) and unusual bruising or bleeding (such as nose bleeds). These studies also showed that the same symptoms affected children and adolescents taking sugar pills (placebo) instead of Paroxat, although these were seen less often. Some patients in these studies of under 18s had withdrawal effects when they stopped taking Paroxat. These effects were mostly similar to those seen in adults after stopping Paroxat (see Section 3, How to take Paroxat). In addition, patients under 18 also commonly (affecting less than 1 in 10) experienced stomach ache, feeling nervous and changing emotions (including crying, changes in mood, trying to hurt themselves, thoughts of suicide and attempting suicide).</p><p>You may find it helpful to tell a relative or close friend&nbsp;that you are depressed or have an anxiety disorder, and ask him to read this leaflet. You might ask him to tell you if he thinks your depression or anxiety is getting worse, or if he is worried about changes in your behavior.</p><p><strong>Taking other medicines</strong></p><p>Please&nbsp;<strong>tell your doctor or pharmacist</strong>&nbsp;if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Especially:</p><ul><li>Monoamine oxidase inhibitors (MAOls, including moclobemide), or have taken them at any time within the last two weeks,</li><li>Thioridazine (a tranquilliser),</li><li>Fentanyl or pethidine (for severe pain),</li><li>Tramadol (a painkiller),</li><li>Medicines called triptans, such as sumatriptan (to treat migraine),</li><li>Other antidepressants including other Selective Serotonin Reuptake Inhibitors (SSRls),</li><li>Drugs to treat some psychiatric conditions such as lithium, perphenazine,</li><li>St John&rsquo;s Wort, (a herbal remedy for depression),</li><li>Linezolid (an antibiotic),</li><li>Methylene blue (used to treat high levels of methaemoglobin in the blood).</li></ul><p>Concomitant use of above-mentioned medicinal products may lead to &lsquo;serotonin syndrome&rsquo; (see &ldquo;Take special care with Paroxat&rdquo;).</p><p>Other drugs taken with Paroxat that may cause unwanted effects include:</p><ul><li>Aspirin, ibuprofen or other medicines called NSAIDs (nonsteroidal anti-inflammatory drugs) such as celecoxib, etodolac, meloxicam and refecoxib (for pain and inflammation),</li><li>Other antidepressants including, tryptophan and tricyclic antidepressants like clomipramine, nortriptyline and desipramine,</li><li>Drugs to treat some psychiatric conditions such as clozapine, risperidone, pimozide,</li><li>Sodium valproate, phenobarbital, phenytoin or carbamazepine (to treat epilepsy),</li><li>Atomoxetine (to treat attention deficit hyperactivity disorder (ADHD)),</li><li>Procyclidine (to relieve tremor, especially in Parkinson&rsquo;s Disease),</li><li>Warfarin or other anticoagulants (to thin the blood),</li><li>Propafenone, flecainide (to treat an irregular heartbeat),</li><li>Tamoxifen (used in breast cancer),</li><li>Fosamprenivir/ritonavir (used in HIV),</li><li>Metoprolol (for high blood pressure and heart problems),</li><li>Rifampicin (to treat tuberculosis (TB) and leprosy).</li><li>Pravastatin, used to treat high cholesterol.</li></ul><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are planning to become pregnant or are breast-feeding ask your doctor or pharmacist for advice before taking this medicine.&nbsp;</p><p><strong>Pregnancy</strong></p><p>If you are already taking Paroxat and have just found out that you are pregnant you should talk to your doctor&nbsp;immediately. This is because some studies have suggested an increase in the risk of heart defects in babies whose mothers received Paroxat in the first few months of pregnancy. These studies found that less than 2 in 100 babies (2%) whose mothers received Paroxat in early pregnancy had a heart defect, compared with the normal rate of 1 in 100 babies (1%) seen in the general population. You and your doctor may decide that it is better for you to gradually stop taking Paroxat while you are pregnant. However, depending on your circumstances, your doctor may suggest that it is better for you to keep taking Paroxat.</p><p>When taken during pregnancy,&nbsp;particularly in the last 3 months&nbsp;of pregnancy, medicines like Paroxat may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN). PPHN increases blood pressure in the blood vessels in the lungs. This may result in abnormal blood flow to the lungs and heart and the baby cannot get enough oxygen into their blood stream. These symptoms usually begin during the first 24 hours after birth and include not being able to sleep or feed properly, breathing faster, a blue-ish skin or being too hot or cold, being sick, crying a lot, stiff or floppy muscles, lethargy, tremors, jitters or fits. If your baby has any of these symptoms when it is born and you are concerned,&nbsp;contact your doctor.</p><p>Observational data indicate an increased risk (less than 2-fold) of postpartum hemorrhage&nbsp;following SSRI/SNRI exposure within the month prior to birth.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>Paroxat has been shown to reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed as yet.</p><p><strong>Driving and using machines</strong></p><p>Paroxat may cause dizziness, confusion or changes in eyesight.</p><p>If you are affected by these side effects, do not drive or use machinery.</p><p><strong>Alcohol</strong></p><p>Do not drink alcohol&nbsp;while you are taking Paroxat. Alcohol may make your symptoms or side effects worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Paroxat exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.</p><p>Take your tablets&nbsp;in the morning with food. Swallow them&nbsp;with a drink of water. The tablets can be cut in half. Do not chew.</p><p><strong>Doses:</strong></p><p>Your doctor will advise you what dose to take when you first start taking Paroxat.</p><ul><li><strong>Adults</strong><ul><li>Depression: 20mg a day to a maximum of 50mg.</li><li>Obsessive compulsive disorder: 20mg a day to a maximum of 60mg.</li><li>Panic disorder: 10mg a day to a maximum of 60mg.</li><li>Social anxiety disorder: 20mg a day to a maximum of 50mg.</li><li>Post traumatic stress disorder: 20mg a day to a maximum of 50mg.</li><li>Anxiety disorder: 20mg a day to a maximum of 50mg.</li></ul></li><li><strong>Elderly</strong>: the maximum dose for people over 65 is 40mg per day.</li><li><strong>Children and adolescents</strong>: not recommended for use in children aged less than 18 years.</li><li><strong>Patients with liver or kidney disease</strong><br />If you have trouble with your liver or kidneys, your doctor may decide that you should have a lower dose. If you have severe liver or kidney disease, the maximum dose is 20mg per day.</li></ul><p><strong>If you take more than you should</strong></p><p>If you (or someone else) swallow a lot of tablets at the same time, or you think a child may have swallowed any, contact your nearest hospital casualty department or tell your doctor immediately. Signs of overdose include being sick, dilated pupils, fever, blood pressure changes, headache, involuntary muscle contractions, agitation, anxiety and rapid heart beat.</p><p><strong>If you forget to take the tablets</strong></p><p>Do not take a double dose to make up for a forgotten dose.&nbsp;If you do forget a dose, and you remember before you go to bed,&nbsp;take it straight away, then take the next dose at the right time.&nbsp;If you only remember during the night, or the next day,&nbsp;leave out the missed dose.</p><p><strong>If you stop taking the tablets</strong></p><p>Do not stop&nbsp;treatment early because your doctor will help you to reduce your dose slowly over a number of weeks or months. This should help reduce the chance of withdrawal effects such as dizziness or a feeling of unsteadiness, tingling, electric shock sensations, burning sensations, sleep disturbances, intense dreams, restlessness, anxiety, feeling sick, shaking, confusion, sweating, headache, diarrhoea, irregular heartbeat, emotional instability, irritability or changes in vision.</p><p>Talk to your doctor&nbsp;before you stop taking the tablets and follow his advice.</p><p><strong>What to do if you&rsquo;re feeling no better</strong></p><p>Paroxat will not relieve your symptoms straight away - all antidepressants take time to work. Some people will start to feel better within a couple of weeks, but for others it may take a little longer. Some people taking antidepressants feel worse before feeling better. If you don&rsquo;t start to feel better after a couple of weeks, go back to your doctor who will advise you. Your doctor should ask to see you again a couple of weeks after you start treatment. Tell your doctor then if you haven&rsquo;t started to feel better.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with other medicines Paroxat can cause side effects, but not everybody gets them.</p><p><strong>Contact your doctor at once if you experience any of the following:</strong></p><ul><li>An allergic reaction: red and lumpy skin rash, fever, blisters or ulcers, swelling of the eyelids, face, lips, mouth or tongue, itching or difficulty breathing or swallowing and feel weak or lightheaded resulting in collapse or loss of consciousness.</li></ul><p>&nbsp;</p><ul><li><strong>Serious skin rashes&nbsp;</strong></li></ul><ul><li>Serious skin rashes are potentially life-threatening and require immediate medical attention. These appear initially as circular patches often with central blisters usually on arms and hands or legs and feet, more severe rashes may include blistering of the chest and back. Additional symptoms such as infection of the eye (conjunctivitis) or ulcers of the mouth, throat or nose may occur. Severe forms of rash may progress to widespread peeling of the skin which can be life threatening. These serious skin rashes are often preceded by headache, fever, body aches (flu-like symptoms).</li></ul><ul><li>Unusual bruising or bleeding, including vomiting blood or passing blood in your stools or urine, bleeding from your gums or nose and prolonged bleeding from cuts.</li><li>Not being able to pass water (urinary retention).</li><li>Seizures (fits).</li><li>Akathisia (restlessness, and feeling like you can&rsquo;t sit or stand still), low blood sodium (causing tiredness, weakness, confusion and achy, stiff or uncoordinated muscles).</li><li>Serotonin syndrome (confusion, restlessness, sweating, shaking, shivering, hallucinations (strange visions or sounds), sudden jerks of the muscles or a fast heartbeat.</li></ul><p>&nbsp;</p><ul><li>Acute glaucoma (eye pain and blurred vision).</li></ul><p>&nbsp;</p><ul><li>If you have <strong>thoughts of harming or killing yourself</strong> at any time, <strong>contact your doctor or go to a hospital straight away.</strong></li></ul><p>&nbsp;</p><p>Tell your doctor if you notice any of the following side effects&nbsp;or notice any other effects not listed:</p><ul><li><strong>Very common</strong>&nbsp;(occurs in more than 1 in 10 users):</li></ul><ul><li><ul><li>Changes in sex drive or function (lack of orgasm, abnormal erection and ejaculation in men), impaired concentration.</li></ul></li></ul><p>&nbsp;</p><ul><li><ul><li>Feeling sick (nausea). Taking your medicine in the morning with food will reduce the chance of this happening.</li></ul></li></ul><ul><li><strong>Common</strong>&nbsp;(occurs in less than 1 in 10 users):</li></ul><ul><li><ul><li>Dry mouth, diarrhoea, constipation, being sick,</li><li>Lack of appetite, weight gain, increase in blood cholesterol levels,</li><li>Difficulty sleeping, abnormal dreams/nightmares, feeling sleepy, dizziness, headache,</li><li>Sweating, shakes (tremors), feeling agitated,</li><li>Blurred vision, yawning.</li></ul></li></ul><p>&nbsp;</p><ul><li><strong>Uncommon</strong>&nbsp;(occurs in less than 1 in 100 users):</li></ul><ul><li><ul><li>Increase or decrease in blood pressure,</li><li>Irregular or fast heartbeat,</li><li>Lack of movement, stiffness, shaking,</li><li>Abnormal movements of the mouth and tongue,</li><li>Abnormal dilated pupils,</li><li>An uncontrollable, involuntary passing of urine (urinary incontinence),</li><li>If you are a diabetic patient you may notice a loss of control of your blood sugar levels whilst taking Paroxetine tablets. Please speak to your doctor about adjusting the dosage of your insulin or diabetes medications,</li><li>Confusion, hallucinations, involuntary body or face movements.</li></ul></li></ul><p>&nbsp;</p><ul><li><strong>Rare</strong>&nbsp;(occurs in less than 1 in 1,000 users):</li></ul><ul><li><ul><li>Abnormal production of breast milk in men and women,</li><li>Slow heartbeat,</li><li>Effects on the liver showing up in liver function tests,</li><li>Panic attacks, overactive behavior or thoughts (mania), feeling detached from yourself (depersonalisation), feeling anxious, restless leg syndrome (RLS),</li><li>Joint or muscle pain.</li></ul></li></ul><p>&nbsp;</p><ul><li><strong>Very rare</strong>&nbsp;(occurs in less than 1 in 10,000 users):</li></ul><ul><li><ul><li>Yellowing of the skin or whites of the eyes due to liver disorders,</li><li>Fluid or water retention which may cause swelling of the arms or legs,</li><li>Sensitivity to sunlight,</li><li>Painful erection of the penis that won&rsquo;t go away.</li></ul></li></ul><p>&nbsp;</p><ul><li><strong>Other possible side effects</strong>&nbsp;(frequency cannot be estimated from the data):</li></ul><ul><li><ul><li>Bone fractures, ringing in the ears (tinnitus), aggression.</li><li>Gastrointestinal disorders: Colitis microscopic.</li><li>Postpartum haemorrhage: This event has been reported for the therapeutic class of&nbsp;SSRIs/SNRIs.</li></ul></li></ul><p dir="rtl">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.&nbsp;</li><li>Store below 30&deg;C.</li><li>Do not use Paroxat after the expiry date stated on the label. The expiry date refers to the last day of that month.</li><li>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active ingredient is Paroxetine hydrochloride.&nbsp;</li></ul><ul><li><strong>Paroxat 10mg Film-coated tablets:</strong> each film-coated tablet contains 11.11mg of Paroxetine hydrochloride (equivalent to 20mg of Paroxetine).</li><li><strong>Paroxat 20mg Film-coated tablets:</strong> each film-coated tablet contains 22.21mg of Paroxetine hydrochloride (equivalent to 20mg of Paroxetine).</li><li><strong>Paroxat 30mg Film-coated tablets:</strong> each film-coated tablet contains 33.32mg of Paroxetine hydrochloride (equivalent to 30mg of Paroxetine).</li></ul><ul><li>The other ingredients are:<strong> </strong>Dibasic Calcium Phosphate Dihydrate, Sodium Starch Glycolate, Polysorbate 80, Hydroxypropyl Cellulose (Klucel EF), Magnesium Stearate, Titanium Dioxide, Purified Talc, Polyethylene Glycol MW 6000, Hydroxypropyl Methylcellulose and Purified Water.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Paroxat 10mg Film-coated tablets: A white to off-white, round, biconvex film-coated tablet engraved with “190” on one side and plain on the other side.
Paroxat 20mg Film-coated tablets: A white to off-white, round, biconvex film-coated tablet engraved with “182” on one side and a breakline on the other side.
Paroxat 30mg Film-coated tablets: A white to off-white, round, biconvex film-coated tablet engraved with “183” on one side and a breakline on the other side.
Pack sizes are 30 Film-coated tablets/pack.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO</strong></p><p>Al-Qassim pharmaceutical plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 November 2020.    
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl">باروكسات ينتمى إلى نوع من الأدوية المضادة للاكتئاب تعرف باسم مثبطات إعادة امتصاص السيروتونين الانتقائية. فمن المعتقد أن انخفاض مستوى هرمون السيروتونين هو سبب لحدوث الاكتئاب وبعض الحالات الأخرى ذات الصلة. يعمل باروكسات على إعادة مستوى هرمون السيروتونين إلى الوضع الطبيعى. يستخدم باروكسات لعلاج الحالات الآتية لدى البالغين:</p><ul><li dir="rtl">الاكتئاب،</li><li dir="rtl">الوسواس القهري،</li><li dir="rtl">اضطرابات الهلع مع أو بدون الخوف من الأماكن المكشوفة (الخوف من الأماكن المفتوحة أو المواقف الجديدة)،</li><li dir="rtl">اضطرابات القلق الاجتماعي / الرهاب الاجتماعي،</li><li dir="rtl">اضطرابات ما بعد الصدمة،</li><li dir="rtl">اضطرابات القلق.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>لا تقم بتناول أقراص باروكسات وأخبر طبيبك المعالج فى أى من الحالات الآتية:</strong></p><ul><li dir="rtl">إذا كنت تعانى من فرط التحسس تجاه مادة باروكسيتين أو أى من المكونات الأخرى لهذا الدواء (والمذكورة فى الفقرة رقم 6)،</li><li dir="rtl">إذا كنت تتناول أدوية تسمى بيموزيد أو مثبطات إنزيم أوكسيديز أحادى الأمين (وتشمل موكلوبيميد)، أو تناولت أياً من هذه الأدوية خلال الأسبوعين الماضيين،</li><li dir="rtl">إذا كنت تتناول مهدئ للأعصاب يسمى ثيوريدازين أو بيموزيد.</li><li dir="rtl">استخدام الأدوية التي تحتوي على لينزوليد، والذي يستخدم لعلاج الالتهابات.</li></ul><p dir="rtl">تحقق من خلال طبيبك المعالج أو الصيدلى قبل البدء فى تناول أقراص باروكسات فى أى من الحالات الآتية:</p><ul><li dir="rtl">إذا كنت تعانى من مشاكل بالعين أو الكلى أو الكبد أو القلب،</li><li dir="rtl">إذا كنت تعانى من الصرع أو لديك تاريخ من الإصابة بنوبات،</li><li dir="rtl">إذا كانت لديك نوبات من الهوس (فرط فى النشاط السلوكى أو الفكرى)،</li><li dir="rtl">إذا كنت تخضع لعلاج بالصدمة الكهربائية،</li><li dir="rtl">إذا كان لديك تاريخ من اضطرابات النزف،</li><li dir="rtl">إذا كنت مصاباً بمرض السكري،</li><li dir="rtl">إذا كنت تتبع نظاماً غذائياً منخفض الصوديوم،</li><li dir="rtl">إذا كنت تعانى من المياه الزرقاء (ضغط في العين).</li></ul><p dir="rtl"><strong>ينبغى توخى الحذر مع أقراص باروكسات&nbsp;</strong></p><p dir="rtl">تواصل مع طبيبك المعالج فى حالة تعرضك لأى أعراض مثل ارتباك، أو أرق، أو تعرق، أو اهتزاز أو رعشة أو هلوسة (رؤية أو سماع أشياء غريبة)، أو هزات مفاجئة بالعضلات أو سرعة ضربات القلب، لأن هذه الأعراض قد تكون علامة على &quot;متلازمة السيروتونين&quot;.</p><p dir="rtl">قد تزيد مثبطات استرداد السيروتونين االنتقائية ومثبطات استرداد السيروتونين والنورابينيفرين من خطر حدوث نزيف ما بعد&nbsp;<br />الوالدة</p><p dir="rtl"><strong>التفكير في الانتحار وتفاقم الاكتئاب أو اضطراب القلق الخاص بك</strong></p><p dir="rtl">إذا كنت مصاباً باكتئاب مع/أو بدون اضطرابات القلق فقد تراودك أحياناً بعض الأفكار حول إيذاء أو قتل نفسك. قد تزيد تلك الأفكار فى بداية العلاج بواسطة مضادات الاكتئاب، حيث تستغرق هذه الأدوية بعض الوقت لتؤدى مفعولها، (عادةً حوالى أسبوعين أو أحياناً أطول من ذلك).</p><p dir="rtl">قد تكون أكثر عرضة للتفكير فى تلك الأشياء فى الحالات الآتية:</p><ul><li dir="rtl">إذا راودتك مسبقاً أفكار حول إيذاء أو قتل نفسك.</li><li dir="rtl">إذا كنت من الشباب البالغين. وقد أظهرت المعلومات المستقاة من التجارب السريرية زيادة مخاطر السلوك الانتحاري لدى البالغين من الشباب (الأقل فى العمر من 25 سنة) المصابين بحالات نفسية وتم علاجهم بواسطة مضادات الاكتئاب.</li></ul><p dir="rtl">إذا كانت لديك أفكار حول إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور.</p><p dir="rtl"><strong>الأطفال والمراهقين الأقل فى العمر من 18 سنة</strong></p><p dir="rtl">يحظر استخدام باروكسات فى حالة الأطفال والمراهقين الأقل فى العمر من 18 سنة. أيضاً المرضى الأقل فى العمر من 18 سنة هم أكثر عرضة لخطر حدوث الأعراض الجانبية مثل محاولات الانتحار والأفكار العدوانية والانتحارية (التفكير بعدوانية فى غالبية الوقت والسلوك المعارض والغضب) عند تناول باروكسات. إذا وصف الطبيب لك (أو لطفلك) باروكسات وأردت مناقشة ذلك الأمر توجه إلى الطبيب. يجب عليك إبلاغ طبيبك المعالج فى حالة تعرضك لحدوث أو تدهور أى من الأعراض السالف ذكرها لك (أو لطفلك) عند تناول باروكسات. أيضاً، لم يتم حتى الآن إثبات آثار السلامة الناجمة عن استخدام باروكسات على المدى الطويل بشأن النمو والنضج والتطور المعرفي والسلوكي في هذه الفئة العمرية. أوضحت الدراسات الخاصة باستخدام باروكسات فى الأطفال الأقل فى العمر من 18 سنة أن الأعراض الجانبية الشائعة والتى تصيب أقل من 1 لكل 10 أطفال/مراهقين هى: زيادة فى الأفكار الانتحارية ومحاولات الانتحار، إيذاء النفس عمداً، عدوانية، سلوك غير ودى، فقدان الشهية، ارتعاش، تعرق غير طبيعى، فرط فى النشاط، هياج، تغير فى المشاعر (بما في ذلك البكاء وتغيرات في المزاج) وكدمات غير معتادة أو نزيف (مثل نزيف الأنف ). وأظهرت هذه الدراسات أيضاً أن نفس الأعراض أثرت على الأطفال والمراهقين عند تناول أقراص السكر (بمعنى علاج وهمي) بدلاً من باروكسات، ومع ذلك فقد كانت أقل فى المعدل فى أغلب الأحيان. تعرض بعض المرضى الأقل فى العمر من 18 سنة فى هذه الدراسات إلى أعراض الانسحاب عند التوقف عن تناول باروكسات. هذه الأعراض تشبه إلى حد كبير تلك التى تحدث فى حالة البالغين بعد التوقف عن تناول باروكسات (انظر الفقرة رقم 3، كيفية تناول أقراص باروكسات). بالإضافة إلى، بعض الأعراض الأخرى الشائعة (التى تصيب أقل من 1 لكل 10) التى تعرض إليها الأطفال الأقل فى العمر من 18 سنة وهى ألم بالمعدة، شعور بالتوتر وتغيرات بالمشاعر (بما فى ذلك البكاء، وتغيرات فى المزاج، ومحاولة إيذاء النفس، والأفكار الانتحارية ومحاولات الانتحار).</p><p dir="rtl">قد يساعدك إبلاغ أحد أقاربك أو أصدقائك المقربين بأنك تعانى من اكتئاب أو اضطراب القلق واطلب منه قراءة هذه النشرة. قد يتسنى لك أن تسأله ليخبرك ما إذا كان يعتقد بأن حالة الاكتئاب أو القلق لديك تزداد سوءً، أو إذا كان قلقاً من تغيرات فى سلوكك.</p><p dir="rtl"><strong>تناول أدوية أخرى</strong></p><p dir="rtl">فضلاً أخبر طبيبك المعالج أو الصيدلى بشأن أى أدوية أخرى تتناولها حالياً أو تناولتها مؤخراً، بما فيها تلك الأدوية التى حصلت عليها بدون وصفة طبية. وبشكل خاص الأدوية التالية:</p><ul><li dir="rtl">مثبطات إنزيم أوكسيديز أحادى الأمين (وتشمل موكلوبيميد)، سواءً كنت تتناولها حالياً أو تناولتها فى أى وقت خلال الأسبوعين الماضيين،</li><li dir="rtl">ثيوريدازين (مهدئ للأعصاب)،</li><li dir="rtl">فنتانيل أو بيثيدين (لعلاج الألم الحاد)،</li><li dir="rtl">ترامادول (قاتل للألم)،</li><li dir="rtl">أدوية تعرف باسم تريبتان، مثل سوماتريبتان (لعلاج الصداع النصفى)،</li><li dir="rtl">أدوية أخرى مضادة للاكتئاب بما فيها أدوية أخرى من مجموعة مثبطات إعادة امتصاص السيروتونين الانتقائية،</li><li dir="rtl">أدوية لعلاج حالات نفسية أخرى مثل الليثيوم أو بيرفينازين،</li><li dir="rtl">عشبة القديس جون (وهى دواء عشبى لعلاج الاكتئاب)،</li><li dir="rtl">لينزوليد (مضاد حيوى)،</li><li dir="rtl">الميثيلين الأزرق (الذى يستخدم لعلاج ارتفاع مستويات الميثيموجلوبين في الدم).</li></ul><p dir="rtl">استخدام الأدوية المذكورة أعلاه بشكل متزامن مع باروكسات قد يؤدى إلى حدوث &lsquo;متلازمة السيروتونين&lsquo; (انظر فقرة &quot; ينبغى توخى الحذر مع أقراص باروكسات&quot;).</p><p dir="rtl">هناك أدوية أخرى قد تسبب تأثيرات غير مرغوب فيها عند تناولها مع باروكسات وتشمل:</p><ul><li dir="rtl">أسبرين، أو إيبوبروفين أو غيرها من الأدوية التى تسمى مضادات الالتهاب غير الستيرويدية مثل سيليكوكسيب، إيتودولاك، ميلوكسيكام و ريفيكوكسيب (لعلاج الألم والالتهاب)،</li><li dir="rtl">مضادات الاكتئاب الأخرى بما في ذلك، تربتوفان ومضادات الاكتئاب ثلاثية الحلقات مثل كلوميبرامين، نورتريبتيلين وديسيبرامين،</li><li dir="rtl">أدوية لعلاج بعض الحالات النفسية مثل كلوزابين، ريسبيريدون، أو بيموزيد،</li><li dir="rtl">فالبروات الصوديوم، أو فينوباربيتال، أو فينيتوين أو كاربامازيبين (لعلاج الصرع)،</li><li dir="rtl">أتوموكسيتين (لعلاج فرط النشاط مع نقص الانتباه)،</li><li dir="rtl">بروسيكليدين (للحد من الاهتزاز، وخاصةً في مرض الشلل الرعاش)،</li><li dir="rtl">وارفارين أو مضادات التخثر الأخرى (لتخفيف لزوجة الدم)،</li><li dir="rtl">بروبافينون، فليكاينيد (لعلاج عدم انتظام ضربات القلب)،</li><li dir="rtl">تاموكسيفين (المستخدم في سرطان الثدي)،</li><li dir="rtl">فوسامبرينيفير / ريتونافير (أدوية تستخدم في فيروس نقص المناعة البشرية)،</li><li dir="rtl">ميتوبرولول (لعلاج ارتفاع ضغط الدم ومشاكل القلب)،</li><li dir="rtl">ريفامبيسين (لعلاج السل والجذام).</li><li dir="rtl">براڨاستاتين، ويستخدم لعلاج ارتفاع الكوليسترول في الدم.</li></ul><p dir="rtl"><strong>الحمل والرضاعة</strong></p><p dir="rtl">إذا كنتِ تخططين للحمل أو ترضعين طفلك طبيعياً اسألى طبيبك المعالج أو الصيدلى للمشورة قبل البدء فى تناول هذا الدواء.&nbsp;</p><p dir="rtl"><strong>الحمل</strong></p><p dir="rtl">إذا كنتِ تخضعين للعلاج بواسطة باروكسات ثم اكتشفتِ أنكِ حامل يجب عليكِ إبلاغ طبيبك المعالج فوراً. وذلك لأن بعض الدراسات أشارت إلى وجود زيادة في خطر تشوهات القلب عند الأطفال الخاضعات أمهاتهم للعلاج بواسطة باروكسات خلال الأشهر القليلة الأولى من فترة الحمل. كشفت تلك الدراسات عن إصابة أقل من 2 لكل 100 طفل (%2) الخاضعات أمهاتهم للعلاج بواسطة باروكسات خلال الفترة الأولى من الحمل بتشوهات بالقلب مقارنةً بالمعدل الطبيعى وهو 1 لكل 100 طفل (%1) فى عموم السكان. قد تقررين مع طبيبك المعالج أنه من الأفضل التوقف تدريجياً عن تناول باروكسات أثناء فترة الحمل. ومع ذلك، قد يقرر طبيبك المعالج أنه من الأفضل لكِ الاستمرار فى تناولك باروكسات اعتماداً على حالتك.</p><p dir="rtl">استخدام بعض الأدوية مثل باروكسات خلال فترة الحمل، وخاصةً في الثلاثة أشهر الأخيرة من الحمل، قد يزيد من خطر حدوث حالة خطيرة في الأطفال تسمى ارتفاع ضغط الدم الرئوي المستمر في حديثي الولادة. وهى ارتفاع ضغط الدم بالأوعية الدموية فى الرئتين. مما قد يؤدى إلى خلل فى تدفق الدم إلى الرئتين والقلب مما يؤدى إلى نقص فى مستوى الأكسجين بالدم لدى الطفل. هذه الأعراض غالباً ما تحدث خلال 24 ساعة الأولى بعد الولادة وتشمل عدم قدرة الطفل على النوم أو الرضاعة بشكل صحيح، وسرعة معدل التنفس، زرقان الجلد أو سخونة أو برودة الجسم، إعياء، بكاء كثير، تصلب أو مرونة بالعضلات، خمول، ارتعاش، توتر أو نوبات. إذا كان طفلك لديه أي من هذه الأعراض عند ولادته، وكنتِ قلقة، اتصلى بطبيبك المعالج.</p><p dir="rtl">تشير بيانات الرصد إلى زيادة خطر )أقل من ضعفين( لنزيف ما بعد الوالدة بعد التعرض لمثبطات استرداد السيروتونين&nbsp;<br />االنتقائية ومثبطات استرداد السيروتونين والنورابينيفرين خالل الشهر السابق للوالدة</p><p dir="rtl"><strong>الخصوبة</strong></p><p dir="rtl">أوضحت الدراسات المجراة على الحيوانات أن باروكسات يقلل من جودة الحيوانات المنوية. نظرياً، قد يؤثر ذلك على الخصوبة، لكن لم يتم رصد تأثير باروكسات على الخصوبة لدى البشر حتى الآن.</p><p dir="rtl"><strong>القيادة واستخدام الآلات</strong></p><p dir="rtl">قد يسبب باروكسات دوخة أو عدم تركيز أو تغيرات فى الرؤية. إذا تأثرت بتلك الأعراض الجانبية، لا تقم بقيادة السيارة أو استخدام الآلات.</p><p dir="rtl"><strong>الكحول</strong></p><p dir="rtl">لا تشرب الكحول أثناء تناول باروكسات. فقد يزيد الكحول من سوء الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl">قم دائماً بتناول باروكسات تماماً كما أخبرك طبيبك المعالج. فى حالة عدم تأكدك، تحقق من خلال طبيبك المعالج أو الصيدلى.</p><p dir="rtl">تناول الجرعة الخاصة بك من أقراص باروكسات فى الصباح مع الطعام. قم بابتلاع القرص مع شرب الماء. القرص قابل للقسمة إلى نصفين. لا تقم بمضغ القرص.</p><p dir="rtl"><strong>الجرعات:</strong></p><p dir="rtl">سيقوم طبيبك المعالج بإرشادك إلى الجرعة المناسبة لك عند البدء فى تناول أقراص باروكسات.</p><ul><li dir="rtl"><strong>للبالغين</strong></li></ul><ul><li dir="rtl">لعلاج الاكتئاب: تكون الجرعة من 20 ملجم فى اليوم إلى ما يصل إلى 50 ملجم كحد أقصى.</li><li dir="rtl">لعلاج الوسواس القهرى: تكون الجرعة من 20 ملجم فى اليوم إلى ما يصل إلى 60 ملجم كحد أقصى.</li><li dir="rtl">اضطرابات الهلع: تكون الجرعة من 10 ملجم فى اليوم إلى ما يصل إلى 60 ملجم كحد أقصى.</li><li dir="rtl">اضطراب القلق الاجتماعي: تكون الجرعة من 20 ملجم فى اليوم إلى ما يصل إلى 50 ملجم كحد أقصى.</li><li dir="rtl">اضطرابات ما بعد الصدمة: تكون الجرعة من 20 ملجم فى اليوم إلى ما يصل إلى 50 ملجم كحد أقصى.</li><li dir="rtl">اضطراب القلق: تكون الجرعة من 20 ملجم فى اليوم إلى ما يصل إلى 50 ملجم كحد أقصى.</li></ul><ul><li dir="rtl"><strong>لكبار السن: </strong>للمرضى الأكبر فى العمر من 65 سنة يكون الحد الأقصى للجرعة 40 ملجم فى اليوم.</li><li dir="rtl"><strong>للأطفال والمراهقين: </strong>يحظر استخدام باروكسات فى حالة الأطفال والمراهقين الأقل فى العمر من 18 سنة.</li><li dir="rtl"><strong>للمرضى المصابين بأمراض بالكلى أو الكبد:</strong></li></ul><p dir="rtl">إذا كانت لديك مشاكل بالكلى أو الكبد فقد يقرر طبيبك المعالج وصف جرعة أقل لك من باروكسات. إذا كنت تعانى من مرض حاد بالكبد أو الكلى فإن الجرعة القصوى المسموح بها هى 20 ملجم فى اليوم.</p><p dir="rtl"><strong>فى حالة تناول أقراص باروكسات أكثر مما ينبغى</strong></p><p dir="rtl">إذا تناولت (أنت أو أى شخص آخر) العديد من أقراص باروكسات فى نفس الوقت أو تظن بأن طفلك تناول أياً من هذه الأقراص، تواصل مع قسم الطوارئ بأقرب مستشفى أو أخبر طبيبك المعالج فى الحال. علامات تناول جرعة مفرطة تشمل: إعياء، اتساع حدقة العين، حمى، تغيرات في ضغط الدم، صداع، تقلصات عضلية لاإرادية، تهيج وقلق وسرعة ضربات القلب.</p><p dir="rtl"><strong>فى حالة نسيان تناول باروكسات</strong></p><p dir="rtl">إذا نسيت تناول الجرعة الخاصة بك من أقراص باروكسات، لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية. إذا تذكرت الجرعة قبل الذهاب إلى النوم، قم بتناولها مباشرةً، ثم تناول الجرعة التالية فى موعدها المحدد. أما إذا تذكرت الجرعة خلال الليل أو فى اليوم التالى اترك الجرعة المنسية.</p><p dir="rtl"><strong>فى حالة التوقف عن تناول أقراص باروكسات</strong></p><p dir="rtl">لا تتوقف عن تناول العلاج مبكراً حيث سيقوم طبيبك المعالج بمساعدتك لتقليل الجرعة الخاصة بك تدريجياً على مدار بضعة أسابيع أو أشهر. مما يساعد على الحد من ظهور أعراض الانسحاب مثل الدوخة أو الشعور بعدم الثبات، الإحساس بوخز، إحساس يشبه الصدمة الكهربائية، الإحساس بحرق، اضطرابات النوم، أحلام مزعجة، أرق، قلق، شعور بالمرض، ارتعاش، ارتباك، تعرق، صداع، إسهال، عدم انتظام ضربات القلب، وعدم الاستقرار العاطفي، تهيج أو تغيرات في الرؤية.</p><p dir="rtl">تواصل مع طبيبك المعالج قبل التوقف عن تناول هذه الأقراص واتبع تعليماته.</p><p dir="rtl"><strong>ما يجب عليك فعله عند شعورك بعدم تحسن حالتك</strong></p><p dir="rtl">لا يؤدى باروكسات مفعوله مباشرةً &ndash; حيث تستغرق كل مضادات الاكتئاب بعض الوقت لتؤدى مفعولها. بعض الناس قد يشعرون ببدء تحسن حالتهم خلال أسبوعين، ولكن لبعض الناس قد تكون المدة أطول بقليل من ذلك. بعض الناس عند استخدامهم لمضادات الاكتئاب قد يشعرون بسوء حالتهم قبل الشعور بتحسن. إذا لم تشعر ببدء تحسن حالتك بعد أسبوعين من العلاج، عد مرة أخرى إلى طبيبك المعالج لاستشارته. ينبغى أن يطلب منك طبيبك المعالج مراجعته مرة أخرى بعد أسبوعين من بداية العلاج. حينئذٍ أخبر طبيبك المعالج فى حالة عدم شعورك ببدء تحسن حالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl">مثل جميع الأدوية قد يسبب باروكسات أعراضاً جانبية، وإن لم تحدث لكل من يتناول هذا الدواء.</p><p dir="rtl"><strong>تواصل مع طبيبك المعالج فى الحال إذا تعرضت لأى من الأعراض التالية:</strong></p><ul><li dir="rtl">تفاعلات تحسسية: طفح جلدى مصحوب باحمرار وتكتل بالجلد، حمى، تقرحات أو بثور، تورم جفون العينين، أو الوجه، أو الشفتين، أو الفم، أو اللسان، حكة أو صعوبة بالتنفس أو البلع والشعور بالضعف أو بالدوار مما يؤدي إلى السقوط أو فقدان الوعي.</li><li dir="rtl"><strong>طفح جلدي خطير</strong></li></ul><ul><li dir="rtl">الطفح الجلدي الحاد يمكن أن يهدد الحياة ويتطلب عناية طبية فورية. و يظهر في البداية علي شكل بقع دائرية يصاحبها عادة ظهور بثور تتمركز عادة على الذراعين واليدين أو الساقين والقدمين، والطفح الجلدي الأكثر حدة من الممكن أن يشمل ظهور تقرحات علي الصدر والظهر. من الممكن أن تظهر أعراض إضافية مثل إلتهاب العين (الملتحمة) أو تقرحات في الفم والحلق أو الأنف. الأشكال الحادة من الطفح الجلدي قد تتطور إلي تقشير على نطاق واسع من الجلد مما قد يمثل تهديدا للحياة. وغالبا ما يسبق هذا الطفح الجلدي الخطير، الصداع والحمى وآلام في الجسم (مثل أعراض الانفلونزا).</li></ul><ul><li dir="rtl">كدمات بشكل غير معتاد أو نزيف ويشمل تقيؤ دموى أو ظهور دم مع البراز أو البول، ونزيف من اللثة أو الأنف والنزيف لفترة طويلة من الجروح القطعية.</li><li dir="rtl">عدم القدرة على التبول (احتباس البول).</li><li dir="rtl">نوبات (تشنجات).</li><li dir="rtl">تعذر الجلوس (أرق، شعور وكأنك لا تستطيع الجلوس أو الوقوف دون حراك)، وانخفاض الصوديوم في الدم (الذي يسبب التعب، والضعف والارتباك، والألم، وتصلب أو عدم التحكم فى العضلات).</li><li dir="rtl">متلازمة السيروتونين (ارتباك، أرق، تعرق، رعشات، اهتزاز، هلاوس (رؤية أو سماع أشياء غريبة)، هزات مفاجئة بالعضلات، أو تسارع ضربات القلب.</li></ul><p dir="rtl">أخبر طبيبك المعالج إذا لاحظت ظهور أى من الأعراض الجانبية التالية أو ظهور أى أعراض جانبية لم يتم ذكرها فى هذه النشرة:</p><ul><li dir="rtl"><strong>شائعة جداً</strong> (والتى قد تصيب أكثر من 1 لكل 10 مستخدمين لهذا الدواء):</li></ul><ul><li dir="rtl">تغيرات في الدافع أو&nbsp; الأداء الجنسي (الافتقار إلى النشوة الجنسية، خلل فى الانتصاب والقذف عند الرجال)، و ضعف التركيز.</li><li dir="rtl">الشعور بالإعياء (الغثيان). تناولك للدواء في الصباح مع الطعام يقلل من فرصة حدوث ذلك.</li></ul><ul><li dir="rtl"><strong>شائعة</strong> (والتى قد تصيب أقل من 1 لكل 10 مستخدمين لهذا الدواء):</li></ul><ul><li dir="rtl">جفاف الفم، إسهال، أو إمساك، أو إعياء،</li><li dir="rtl">فقدان الشهية، أو زيادة الوزن، أو زيادة مستوى الكوليستيرول بالدم،</li><li dir="rtl">صعوبة النوم، أحلام مزعجة/كوابيس، شعور بالنعاس، دوخة، صداع،</li><li dir="rtl">رعشات (اهتزازات)، شعور بالهياج،</li><li dir="rtl">عدم وضوح الرؤية، تثاؤب.</li></ul><ul><li dir="rtl"><strong>غير شائعة</strong> (والتى قد تصيب أقل من 1 لكل 100 مستخدم لهذا الدواء):</li></ul><ul><li dir="rtl">ارتفاع أو انخفاض ضغط الدم،</li><li dir="rtl">عدم انتظام أو تسارع فى ضربات القلب،</li><li dir="rtl">قلة الحركة، تصلب، اهتزاز،</li><li dir="rtl">حركات غير طبيعية بالفم واللسان،</li><li dir="rtl">اتساع غير طبيعى فى حدقة العين،</li><li dir="rtl">عدم القدرة علي التحكم في البول ومروره بصورة لاإرادية (السلس البولي)،</li><li dir="rtl">إذا كنت مصابا بمرض السكري قد تلاحظ فقدان السيطرة على مستويات السكر في الدم خلال فترة تناولك لأقراص الباروكستين. فضلا قم بالتحدث مع طبيبك حول ضبط جرعة الإنسولين الخاصة بك أو أدوية علاج مرض السكري الأخري،</li><li dir="rtl">الارتباك، والهلوسة، وحركات لاإرادية للجسم والوجه.</li></ul><ul><li dir="rtl"><strong>نادرة</strong> (والتى قد تصيب أقل من 1 لكل 1000 مستخدم لهذا الدواء):</li></ul><ul><li dir="rtl">إفراز غير طبيعى فى لبن الثدى لدى الرجال والنساء،</li><li dir="rtl">تباطؤ نبضات القلب،</li><li dir="rtl">تأثيرات على الكبد تتمثل فى ارتفاع وظائف الكبد،</li><li dir="rtl">نوبات الهلع، فرط فى النشاط فى السلوك والفكر (الهوس)، شعور بتشتت عن النفس (اختلال الأنية)، وشعور بالقلق، ومتلازمة تململ الساقين،</li><li dir="rtl">آلام المفاصل أو العضلات.</li></ul><ul><li dir="rtl"><strong>نادرة جداً </strong>(والتى قد تصيب أقل من 1 لكل 10,000 مستخدم لهذا الدواء):</li></ul><ul><li dir="rtl">اصفرار الجلد أو اصفرار بياض العينين&nbsp; نتيجة مرض كبدي،</li><li dir="rtl">احتباس السوائل أو الماء مما قد يؤدى إلى تورم الذراعين أو الساقين،</li><li dir="rtl">الحساسية تجاه ضوء الشمس،</li><li dir="rtl">انتصاب مستمر ومؤلم بالقضيب.</li></ul><ul><li dir="rtl"><strong>أعراض جانبية أخرى محتملة الحدوث</strong> (لم يستدل على معدل تكرارها من خلال المعلومات المتاحة):</li><li dir="rtl">كسور بالعظام، طنين بالأذنين، وعدوانية.</li><li dir="rtl">اضطرابات الجهاز الهضمي: التهاب القولون المجهري.</li><li dir="rtl">نزيف ما بعد الوالدة: تم اإلبالغ عن هذا العرض الجانبي للفئة العالجية من مثبطات استرداد السيروتونين االنتقائية&nbsp;<br />ومثبطات استرداد السيروتونين والنورابينيفرين.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="rtl">يحفظ هذا الدواء بعيداً عن متناول ونظر الأطفال.</li><li dir="rtl">يحفظ هذا الدواء فى درجة حرارة أقل من 30 درجة مئوية.</li><li dir="rtl">لا تستعمل أقراص باروكسات بعد انتهاء تاريخ الصلاحية المدون على العبوة. وتاريخ الانتهاء يشير إلى آخر يوم فى الشهر المذكور.</li><li dir="rtl">يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الاعتبارات ستعمل على حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>محتويات أقراص باروكسات</strong></p><ul><li dir="rtl">المادة الفعالة هى: باروكسيتين هيدروكلورايد.</li></ul><ul><li dir="rtl"><strong>باروكسات 10 ملجم أقراص مغلفة بطبقة رقيقة:</strong> يحتوي كل قرص مغلف بطبقة رقيقة على 11.11 ملجم من باروكسيتين هيدروكلورايد (بما يكافئ 10 ملجم من مادة باروكسيتين).</li><li dir="rtl"><strong>باروكسات 20 ملجم أقراص مغلفة بطبقة رقيقة:</strong> يحتوي كل قرص مغلف بطبقة رقيقة على 22.21 ملجم من باروكسيتين هيدروكلورايد (بما يكافئ 20 ملجم من مادة باروكسيتين).</li><li dir="rtl"><strong>باروكسات 30 ملجم أقراص مغلفة بطبقة رقيقة:</strong> يحتوي كل قرص مغلف بطبقة رقيقة على 33.32 ملجم من باروكسيتين هيدروكلورايد (بما يكافئ 30 ملجم من مادة باروكسيتين).</li></ul><ul><li dir="rtl">مكونات أخرى وهى: فوسفات كالسيوم ثنائي القاعدة ثنائي التميه، جليكولات نشا الصوديوم، بوليسوربات 80، هيدروكسي بروبيل سيليولوز، ستيارات مغنيسيوم، ثاني أكسيد تيتانيوم، تلك منقى، بولي إيثيلين جليكول <strong>MW 6000</strong>، هيدروكسي بروبيل ميثيل سيليولوز ومياه منقاة.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="rtl"><strong>باروكسات 10 ملجم أقراص مغلفة بطبقة رقيقة:</strong> هى أقراص لونها من أبيض إلى أبيض فاتح مستديرة، ثنائية التحدب،<strong> </strong>مغلفة بطبقة رقيقة محفور على أحد جانبيها رقم &quot;190&quot; وعادية على الجانب الآخر.</li><li dir="rtl"><strong>باروكسات 20 ملجم أقراص مغلفة بطبقة رقيقة:</strong> هى أقراص لونها من أبيض إلى أبيض فاتح مستديرة، ثنائية التحدب،<strong> </strong>مغلفة بطبقة رقيقة محفور على أحد جانبيها رقم &quot;182&quot; وبها حد للقسمة من الجانب الآخر.</li><li dir="rtl"><strong>باروكسات 30 ملجم أقراص مغلفة بطبقة رقيقة:</strong> هى أقراص لونها من أبيض إلى أبيض فاتح مستديرة، ثنائية التحدب،<strong> </strong>مغلفة بطبقة رقيقة محفور على أحد جانبيها رقم &quot;183&quot; وبها حد للقسمة من الجانب الآخر.</li></ul><p dir="rtl">تتوفر أقراص باروكسات في عبوة تحتوي كل منها على 30 قرصاً مغلفاً بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>الدوائية</strong></p><p dir="rtl">مصنع الأدوية بالقصيم</p><p dir="rtl">المملكة العربية السعودية</p><p dir="rtl">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             نوفمبر 2020.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paroxat 10 mg Film-coated tablets.
Paroxat 20 mg Film-coated tablets.
Paroxat 30 mg Film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                − Paroxat 10mg Film-coated tablets: each film-coated tablet contains 11.11mg of
Paroxetine hydrochloride (equivalent to 20mg of Paroxetine).
− Paroxat 20mg Film-coated tablets: each film-coated tablet contains 22.21mg of 
Paroxetine hydrochloride (equivalent to 20mg of Paroxetine).
− Paroxat 30mg Film-coated tablets: each film-coated tablet contains 33.32mg of 
Paroxetine hydrochloride (equivalent to 30mg of Paroxetine).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
Paroxat 10mg FC Tablets :A white to off-white, round, biconvex film-coated tablet engraved with “190” on one side and plain on the other side.
Paroxat 20mg FC Tablets :  A white to off-white, round, biconvex film-coated tablet engraved with “182” on one side and a breakline on the other side
Paroxat 30mg FC Tablets : A white to off-white, round, biconvex film-coated tablet engraved with “183” on one side and a breakline on the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of<br />- Major depressive episode.<br />- Obsessive compulsive disorder (OCD).<br />- Panic disorder with or without agoraphobia.<br />- Social anxiety disorder/social phobia.<br />- Generalized anxiety disorder.<br />- Post-traumatic stress disorde</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>It is recommended that paroxetine is administered once daily in the morning with food.<br /><strong>Major depressive episode</strong><br />The recommended dose is 20 mg daily. In general, improvement in patients starts after one week&nbsp;<br />but may only become evident from the second week of therapy.<br />As with all antidepressant medicinal products, dosage should be reviewed and adjusted if&nbsp;<br />necessary within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically&nbsp;<br />appropriate. In some patients, with insufficient response to 20 mg, the dose may be increased&nbsp;<br />gradually up to a maximum of 50 mg a day in 10 mg steps according to the patient&rsquo;s response.<br />Patients with depression should be treated for a sufficient period of at least 6 months to ensure&nbsp;<br />that they are free from symptoms.<br /><strong>Obsessive compulsive disorder</strong><br />The recommended dose is 40 mg daily. Patients should start on 20 mg/day and the dose may be&nbsp;<br />increased gradually in 10 mg increments to the recommended dose. If after some weeks on the&nbsp;<br />recommended dose insufficient response is seen, some patients may benefit from having their&nbsp;<br />dose increased gradually up to a maximum of 60 mg/day.<br />Patients with OCD should be treated for a sufficient period to ensure that they are free from&nbsp;<br />symptoms. This period may be several months of even longer (see section 5.1).<br /><strong>Panic disorder</strong><br />The recommended dose is 40 mg daily. Patients should be started on 10 mg/day and the dose&nbsp;<br />gradually increased in 10 mg steps according to the patient&#39;s response up to the recommended&nbsp;<br />dose. A low initial starting dose is recommended to minimize the potential worsening of panic&nbsp;<br />symptomatology, which is generally recognised to occur early in the treatment of this disorder.<br />If, after some weeks on the recommended dose, insufficient response is seen, some patients may&nbsp;<br />benefit from having their dose increased gradually up to a maximum of 60 mg/day.<br />Patients with panic disorder should be treated for a sufficient period to ensure that they are free&nbsp;<br />from symptoms. This period may be several months or even longer (see section 5.1).<br /><strong>Social anxiety disorder/social phobia</strong><br />The recommended dose is 20 mg daily. If, after some weeks on the recommended dose,&nbsp;<br />insufficient response is seen, some patients may benefit from having their dose increased&nbsp;<br />gradually in 10 mg steps up to a maximum of 50 mg/day.<br />Long-term use should be regularly evaluated (see section 5.1).<br /><strong>Generalised anxiety disorder:</strong></p><p>The recommended dose is 20 mg daily. If, after some weeks on the recommended dose,&nbsp;<br />insufficient response is seen, some patients may benefit from having their dose increased&nbsp;<br />gradually in 10 mg steps up to a maximum of 50 mg/day. Long-term use should be regularly&nbsp;<br />evaluated (see section 5.1).<br /><strong>Post-traumatic stress disorder</strong><br />The recommended dose is 20mg daily. If after some weeks on the recommended dose&nbsp;<br />insufficient response is seen some patients may benefit from having their dose increased&nbsp;<br />gradually in 10mg steps up to a maximum of 50mg/day. Long-term use should be regularly&nbsp;<br />evaluated (see section 5.1).<br /><strong><em>General information</em></strong><br /><em>Withdrawal symptoms seen on discontinuation of Paroxat.</em><br />Abrupt discontinuation should be avoided (see section 4.4 and section 4.8).<br />The taper phase regimen used in clinical trials involved decreasing the daily dose by 10 mg at&nbsp;<br />weekly intervals. If intolerable symptoms occur following a decrease in the dose or upon&nbsp;<br />discontinuation of treatment, then resuming the previously prescribed dose may be considered.&nbsp;<br />Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.<br /><em><strong>Special populations</strong><br />Elderly</em><br />Increased plasma concentrations of paroxetine occur in elderly subjects, but the range of&nbsp;<br />concentrations overlaps with that observed in younger subjects.<br />Dosing should commence at the adult starting dose. Increasing the dose might be useful in some&nbsp;<br />patients, but the maximum dose should not exceed 40 mg daily.<br /><em><strong>Children and adolescents (7-17 years)</strong></em><br />Paroxat should not be used for the treatment of children and adolescents as controlled clinical&nbsp;<br />trials have found paroxetine to be associated with increased risk for suicidal behaviour and&nbsp;<br />hostility. In addition, in these trials, efficacy has not been adequately demonstrated (see section&nbsp;<br />4.4 and section 4.8).<br /><em>Children aged below 7 years</em><br />The use of paroxetine has not been studied in children less than 7 years.<br />Paroxetine should not be used, as long as safety and efficacy in this age group have not been&nbsp;<br />established.<br />Renal/Hepatic Impairment:<br />Increased plasma concentrations of paroxetine occur in patients with severe renal impairment&nbsp;<br />(creatinine clearance less than 30 ml/min) or in those with hepatic impairment. Therefore, dosage&nbsp;<br />should be restricted to the lower end of the dosage range.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to paroxetine or any of the excipients.
Paroxat is contraindicated in combination with monoamine oxidase inhibitors (MAOIs). 
Treatment with Paroxat can be initiated:
- Two weeks after discontinuation of an irreversible MAOI, or
- At least 24 hours after discontinuation of a reversible MAOI (e.g. moclobemide).
At least one week should elapse between discontinuation of Paroxat and initiation of therapy 
with any MAOI.
Paroxat should not be used in combination with thioridazine, because, as with other drugs which 
inhibit the hepatic enzyme CYP450 2D6, Paroxat can elevate plasma levels of thioridazine (see section 4.5). Administration of thioridazine alone can lead to QTc interval prolongation with 
associated serious ventricular arrhythmia such as torsades de pointes, and sudden death.
- Paroxetine should not be used in combination with pimozide.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Paroxat should be initiated cautiously two weeks after terminating treatment with&nbsp;<br />an irreversible MAOI or 24 hours after terminating treatment with a reversible MAO inhibitor.&nbsp;<br />Dosage of Paroxat should be increased gradually until an optimal response is reached (see&nbsp;<br />section 4.3 and section 4.5).<br /><strong><em>Children and adolescents (7-17 years)</em></strong><br />Paroxat should not be used in the treatment of children and adolescents under the age of 18&nbsp;<br />years. In clinical trials, increased suicidal-related behaviours (suicide attempts and suicidal&nbsp;<br />thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more<br />frequently observed in children and adolescents treated with paroxetine compared to those&nbsp;<br />treated with placebo. In addition, in these trials, efficacy has not been adequately demonstrated&nbsp;<br />and long-term safety data in children and adolescents concerning growth, maturation and&nbsp;<br />cognitive and behavioural development are lacking (see section 4.8).<br /><em><strong>Suicide/suicidal ideation</strong></em><br />Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide. This&nbsp;<br />risk persists until significant remission occurs. As improvement may not occur during the first&nbsp;<br />few weeks or more of treatment, patients should be closely monitored until such improvement&nbsp;<br />occurs. It is general clinical experience with all antidepressant therapies that the risk of suicide&nbsp;<br />may increase in the early stages of recovery.<br />Other psychiatric conditions for which Paroxat is prescribed can also be associated with an&nbsp;<br />increased risk of suicidal behaviour. In addition, these conditions may be co-morbid with major&nbsp;<br />depressive disorder. The same precautions observed when treating patients with major depressive&nbsp;<br />disorder should therefore be observed when treating patients with other psychiatric disorders.<br />Patients with a history of suicidal behaviour or thoughts, or those exhibiting a significant degree&nbsp;<br />of suicidal ideation prior to commencement of treatment are at a greater risk of suicidal thoughts&nbsp;<br />or suicide attempts, and should receive careful monitoring during treatment.<br />There is a possibility of an increased risk of suicide-related behaviour in young adults aged 18-<br />29. Young adults should therefore be monitored carefully throughout treatment.<br />There are insufficient data concerning the risk of suicide-related behaviour in treatment-na&iuml;ve&nbsp;<br />patients, but careful monitoring might be warranted.<br />Patients (and caregivers of patients) should be alerted about the need to monitor for the&nbsp;<br />emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical&nbsp;<br />advice immediately if these symptoms occur.<br /><strong><em>Akathisia</em></strong><br />The use of Paroxat has been associated with the development of akathisia, which is characterised&nbsp;<br />by an inner sense of restlessness and psychomotor agitation such as an inability to sit or stand&nbsp;<br />still usually associated with subjective distress. This is most likely to occur within the first few<br />weeks of treatment. In patients who develop these symptoms, increasing the dose may be&nbsp;<br />detrimental.<br /><strong><em>Serotonin syndrome/neuroleptic malignant syndrome</em></strong><br />On rare occasions, development of a serotonin syndrome or neuroleptic malignant syndrome-like&nbsp;<br />events may occur in association with treatment with Paroxat, particularly when given in&nbsp;<br />combination with other serotonergic and/or neuroleptic drugs. As these syndromes may result in&nbsp;potentially lifethreatening conditions, treatment with Paroxat should be discontinued if such&nbsp;<br />events (characterised by clusters of symptoms such as hyperthermia, rigidity, myoclonus,&nbsp;<br />autonomic instability with possible rapid fluctuations of vital signs, mental status changes&nbsp;<br />including confusion, irritability, extreme agitation progressing to delirium and coma) occur and&nbsp;<br />supportive symptomatic treatment should be initiated. Paroxat should not be used in combination<br />with serotonin precursors (such as L-tryptophan, oxitriptan) due to the risk of serotonergic&nbsp;<br />syndrome (see section 4.3 and section 4.5).<br /><em><strong>Mania</strong></em><br />As with all antidepressants, Paroxat should be used with caution in patients with a history of&nbsp;<br />mania. Paroxat should be discontinued in any patient entering a manic phase.<br /><em><strong>Renal/hepatic impairment</strong></em><br />Caution is recommended in patients with severe renal impairment or in those with hepatic&nbsp;<br />impairment (see section 4.2).<br /><strong>Diabetes</strong><br />In patients with diabetes, treatment with an SSRI may alter glycaemia control.<br />Insulin and/or oral hypoglycaemic dosage may need to be adjusted.<br /><strong>Epilepsy</strong><br />As with other antidepressants, Paroxat should be used with caution in patients with epilepsy.<br /><strong>Seizures</strong><br />Overall, the incidence of seizures is less than 0.1% in patients treated with Paroxat. Paroxat&nbsp;<br />should be discontinued in any patient who develops seizures.<br /><strong>Electroconvulsive therapy (ECT)</strong><br />There is little clinical experience of concurrent administration of Paroxat with Electroconvulsive<br />therapy (ECT).<br /><strong>Glaucoma</strong><br />As with other SSRIs, paroxetine infrequently causes mydriasis and should be used with caution&nbsp;<br />in patients with narrow-angle glaucoma or history of glaucoma.<br /><strong>Cardiac conditions</strong><br />The usual precautions should be observed in patients with cardiac conditions.<br /><strong>Hyponatraemia</strong><br />Hyponatraemia has been reported rarely, predominantly in the elderly. Caution should also be&nbsp;<br />exercised in those patients at risk of hyponatraemia e.g. from concomitant medications and&nbsp;<br />cirrhosis. The hyponatraemia generally reverses on discontinuation of Paroxat.<br /><strong>Haemorrhage</strong><br />There have been reports of cutaneous bleeding abnormalities such as ecchymoses and purpura&nbsp;<br />with SSRIs. Other haemorrhagic manifestations e.g. gastrointestinal haemorrhage have been&nbsp;<br />reported. Elderly patients may be at an increased risk.<br />Caution is advised in patients taking SSRIs concomitantly with oral anticoagulants, drugs known&nbsp;<br />to affect platelet function or other drugs that may increase the risk of bleeding (e.g. atypical&nbsp;<br />antipsychotics such as clozapine, phenothiazines, most TCAs, acetylsalicylic acid, NSAIDs,&nbsp;<br />COX-2 inhibitors) as well as in patients with a history of bleeding disorders or conditions which<br />may predispose to bleeding.<br /><strong>SSRIs/SNRIs may increase the risk of postpartum hemorrhage.</strong></p><p><strong>Interaction with tamoxifen</strong><br />Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancer&nbsp;<br />relapse/mortality, may be reduced when co-prescribed with paroxetine as a result of paroxetine&#39;s&nbsp;<br />irreversible inhibition of CYP2D6 (see section 4.5). Paroxetine should whenever possible be&nbsp;<br />avoided during tamoxifen use for treatment or prevention of breast cancer.<br /><strong>Withdrawal symptoms seen on discontinuation of Paroxat treatment</strong><br />Withdrawal symptoms when treatment is discontinued are common, particularly if&nbsp;<br />discontinuation is abrupt (see section 4.8). In clinical trials, adverse events seen on treatment&nbsp;<br />discontinuation occurred in 30% of patients treated with paroxetine compared to 20% of patients&nbsp;<br />treated with placebo. The occurrence of withdrawal symptoms is not the same as the drug being<br />addictive or dependence-producing.<br />The risk of withdrawal symptoms may be dependent on several factors including the duration&nbsp;<br />and dose of therapy and the rate of dose reduction.<br />Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep&nbsp;<br />disturbances (including intense dreams), agitation of anxiety, nausea, tremor, confusion,&nbsp;<br />sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual&nbsp;<br />disturbances have been reported. Generally, these symptoms are mild to moderate, however, in<br />some patients they may be severe in intensity. They usually occur within the first few days of&nbsp;<br />discontinuing treatment, but there have been very rare reports of such symptoms in patients who&nbsp;<br />have inadvertently missed a dose.<br />Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though in some&nbsp;<br />individuals they may be prolonged (2-3 months or more). It is therefore advised that Paroxat&nbsp;<br />should be gradually tapered when discontinuing treatment, over a period of several weeks or&nbsp;<br />months, according to the patient&#39;s needs (see &quot;Withdrawal symptoms seen on discontinuation of<br />Paroxat &ldquo;section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Serotonergic drugs</strong><br />As with other SSRIs, co-administration with serotonergic drugs (including MAOIs, Ltryptophan, triptans, tramadol, linezolid, SSRIs, lithium and St John&#39;s Wort &ndash; Hypericum&nbsp;<br />perforatum - preparations) may lead to an incidence of 5-HT associated effects (serotonin&nbsp;<br />syndrome: see section 4.3 and section 4.4).<br />Caution should be advised and a closer clinical monitoring is required when these drugs are&nbsp;<br />combined with Paroxat.<br /><strong>Drug-metabolising enzymes</strong><br />The metabolism and pharmacokinetics of Paroxat may be affected by the induction or inhibition&nbsp;<br />of drug-metabolising enzymes. When Paroxat is to be co-administered with a known drugmetabolising enzyme inhibitor, consideration should be given to using doses at the lower end of&nbsp;<br />the range. No initial dosage adjustment is considered necessary when the drug is to be&nbsp;<br />coadministered with known drug-metabolising enzyme inducers (e.g. carbamazepine, rifampicin,&nbsp;<br />phenobarbital, phenytoin). Any subsequent dosage adjustment should be guided by clinical effect<br />(tolerability and efficacy).<br /><strong>Procyclidine</strong><br />Daily administration of Paroxat significantly increases the plasma levels of procyclidine. If anticholinergic effects are seen, the dose of procyclidine should be reduced.<br /><strong>Anticonvulsants: carbamazepine, phenytoin, sodium valproat</strong></p><p>Concomitant administration does not seem to show any effect on the pharmacokinetic/dynamic&nbsp;<br />profile in epileptic patients.<br /><strong>CYP2D6 inhibitory potency of paroxetine</strong><br />As with other antidepressants, including other SSRIs, paroxetine inhibits the hepatic cytochrome&nbsp;<br />P450 enzyme CYP2D6. Inhibition of CYP2D6 may lead to increased plasma concentrations of&nbsp;<br />co-administered drugs metabolised by this enzyme. These include certain tricyclic&nbsp;<br />antidepressants (e.g. clomipramine, nortriptyline, and desipramine), phenothiazine neuroleptics<br />(e.g. perphenazine and thioridazine, see section 4.3), risperidone, certain Type Ic antiarrhythmics&nbsp;<br />(e.g. propafenone and flecainide) and metoprolol. It is not recommended to use paroxetine in&nbsp;<br />combination with metoprolol when given in cardiac insufficiency, because of the narrow&nbsp;<br />therapeutic index of metoprolol in this indication.<br /><strong>Tamoxifen</strong><br />Tamoxifen has an important active metabolite, endoxifen, which is produced by CYP2D6 and&nbsp;<br />contributes significantly to the efficacy of tamoxifen. Irreversible inhibition of CYP2D6 by&nbsp;<br />paroxetine leads to reduced plasma concentrations of endoxifen (see section 4.4).<br /><strong>Alcohol</strong><br />As with other psychotropic drugs, patients should be advised to avoid alcohol while taking&nbsp;<br />paroxetine.<br /><strong>Oral anticoagulants</strong><br />A pharmacodynamic interaction between paroxetine and oral anticoagulants may occur.&nbsp;<br />Concomitant use of paroxetine and oral anticoagulants can lead to increased anticoagulant&nbsp;<br />activity and haemorrhagic risk. Therefore, paroxetine should be used with caution in patients&nbsp;<br />who are treated with oral anticoagulants (see section 4.4).<br /><strong>NSAIDs and acetylsalicylic acid, and other antiplatelet agents</strong><br />A pharmacodynamic interaction between paroxetine and NSAIDs/acetylsalicylic acid may occur.&nbsp;<br />Concomitant use of paroxetine and NSAIDs/acetylsalicylic acid can lead to an increased&nbsp;<br />haemorrhagic risk (see section 4.4).<br />Caution is advised in patients taking SSRIs concomitantly with oral anticoagulants, drugs known&nbsp;<br />to affect platelet function or increase the risk of bleeding (e.g. atypical antipsychotics such as&nbsp;<br />clozapine, phenothiazines, most TCAs, acetylsalicylic acid, NSAIDs, COX-2 inhibitors) as well&nbsp;<br />as in patients with a history of bleeding disorders or conditions which may predispose to<br />bleeding.<br /><strong>Pravastatin</strong><br />An interaction between paroxetine and pravastatin has been observed in studies suggesting that&nbsp;<br />co-administration of paroxetine and pravastatin may lead to an increase in blood glucose levels.&nbsp;<br />Patients with diabetes mellitus receiving both paroxetine and pravastatin may require dosage&nbsp;<br />adjustment of oral hypoglycaemic agents and/or insulin (see section 4.4).<br /><strong>Pimozide</strong><br />Increased pimozide levels of on average 2.5 times have been demonstrated in a study of a single&nbsp;<br />low dose pimozide (2 mg) when co-administered with 60 mg paroxetine. This may be explained&nbsp;<br />by the known CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index&nbsp;<br />of pimozide and its known ability to prolong QT interval, concomitant use of pimozide and&nbsp;<br />paroxetine is contraindicated (see section 4.3).</p><p><strong>Fosamprenavir/ritonavir</strong><br />Co-administration of fosamprenavir/ritonavir 700/100 mg twice daily with paroxetine 20 mg&nbsp;<br />daily in healthy volunteers for 10 days significantly decreased plasma levels of paroxetine by&nbsp;<br />approximately 55%. The plasma levels of fosamprenavir/ritonavir during co-administration of&nbsp;<br />paroxetine were similar to reference values of other studies, indicating that paroxetine had no&nbsp;<br />significant effect on metabolism of fosamprenavir/ritonavir. There are no data available about&nbsp;<br />the effects of long-term co-administration of paroxetine and fosamprenavir/ritonavir exceeding&nbsp;<br />10 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong><br /><em>Pregnancy category: D<br />Data on a limited number of exposed pregnancies provide no indication of an increased risk of&nbsp;<br />congenital malformations in the newborn.<br />Paroxat should only be used during pregnancy when strictly indicated.<br />Women planning a pregnancy and those becoming pregnant during therapy should be asked to&nbsp;<br />consult their physician. Abrupt discontinuation should be avoided during pregnancy (see&nbsp;<br />&quot;Withdrawal symptoms seen on discontinuation of Paroxat &quot;, section 4.2).<br />Neonates should be observed if maternal use of Paroxat continues into the later stages of&nbsp;<br />pregnancy, particularly the third trimester.<br />The following symptoms may occur in the neonate after maternal Paroxat use in the later stages&nbsp;<br />of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding&nbsp;<br />difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness,&nbsp;<br />irritability, lethargy, constant crying, somnolence and difficulty in sleeping. These symptoms&nbsp;<br />could be due to either serotonergic effects or withdrawal symptoms. In a majority of instances&nbsp;<br />the complications begin immediately or soon (&lt; 24 hours) after delivery.<br />Animal studies showed reproductive toxicity, but did not indicate direct harmful effects with&nbsp;<br />respect to pregnancy, embryonal/fetal development, parturition or post-natal development (see&nbsp;<br />section 5.3).<br />Observational data indicate an increased risk (less than 2-fold) of postpartum hemorrhage&nbsp;following SSRI/SNRI exposure within the month prior to birth.</em><br /><strong><em>Lactation</em></strong><br /><em>Small amounts of Paroxat are excreted into breast milk. In published studies, serum&nbsp;<br />concentrations in breast-fed infants were undetectable (&lt; 2 ng/ml) or very low (&lt; 4 ng/ml). No&nbsp;<br />signs of drug effects were observed in these infants. Nevertheless, Paroxat should not be used&nbsp;<br />during lactation unless the expected benefits to the mother justify the risks for the infant</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience has shown that therapy with Paroxat is not associated with impairment of&nbsp;<br />cognitive or psychomotor function. However, as with all psychoactive drugs, patients should be&nbsp;<br />cautioned about their ability to drive a car and operate machinery.<br />Although Paroxat does not increase the mental and motor skill impairments caused by alcohol,&nbsp;<br />the concomitant use of Paroxat and alcohol is not advised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some of the adverse drug reactions listed below may decrease in intensity and frequency with&nbsp;continued treatment and do not generally lead to cessation of therapy. Adverse drug reactions are&nbsp;listed below by system organ class and frequency. Frequencies are defined as very common(&ge;1/10), common (&ge;1/100, &lt;1/10), uncommon (&ge;1/1,000, &lt;1/100), rare (&ge;1/10,000, &lt;1/1,000),<br />very rare (&lt;1/10,000), including isolated reports.<br /><strong>Blood and lymphatic system disorders</strong><br />Uncommon: abnormal bleeding, predominantly of the skin and mucous membranes (mostly&nbsp;<br />ecchymosis).<br />Very rare: thrombocytopenia.<br /><strong>Immune system disorders</strong><br />Very rare: allergic reaction (including urticaria and angioedema).<br /><strong>Endocrine disorders</strong><br />Very rare: syndrome of inappropriate anti-diuretic hormone secretion (SIADH).<br /><strong>Metabolism and nutrition disorders</strong><br />Common: increases in cholesterol levels, decreased appetite.<br />Uncommon: Altered glycaemic control has been reported in diabetic patients (see section 4.4).<br />Rare: hyponatraemia.<br />Hyponatraemia has been reported predominantly in elderly patients and is sometimes due to&nbsp;SIADH.<br /><strong>Psychiatric disorders</strong><br />Common: somnolence, insomnia, agitation, abnormal dreams (including nightmares).<br />Uncommon: confusion, hallucinations.<br />Rare: manic reactions, agitation, anxiety, depersonalisation, panic attacks, akathisia (see section&nbsp;4.4)<br />Frequency not known: suicidal ideation and suicidal behaviour. aggression*.<br />Cases of suicidal ideation and suicidal behaviours have been reported during paroxetine therapy&nbsp;or early after treatment discontinuation (see section 4.4).<br />These symptoms may also be due to the underlying disease.<br />*cases of aggression were observed in post marketing experience<br /><strong>Nervous system disorders</strong><br />Very common: concentration impaired.<br />Common: dizziness, tremor, headache.<br />Uncommon: extrapyramidal disorders<br />Rare: convulsions, restless legs syndrome (RLS).<br />Very rare: serotonin syndrome (symptoms may include agitation, confusion, diaphoresis,&nbsp;hallucinations, hyperreflexia, myoclonus, shivering, tachycardia and tremor)<br />Reports of extrapyramidal disorder including oro-facial dystonia have been received in patients&nbsp;sometimes with underlying movement disorders or who were using neuroleptic medication.</p><p><strong>Eye disorders</strong><br />Common: blurred vision.<br />Uncommon: mydriasis (see section 4.4).<br />Very rare: acute glaucoma.<br /><strong>Ear and labyrinth disorders</strong><br />Frequency not known: tinnitus.<br /><strong>Cardiac disorders</strong><br />Uncommon: sinus tachycardia.<br />Rare: bradycardia.<br /><strong>Vascular disorders</strong><br />Uncommon: transient increases or decreases in blood pressure, postural hypotension</p><p>Transient increases of decreases in blood pressure have been reported following treatment with&nbsp;<br />paroxetine, usually in patients with pre-existing hypertension or anxiety.<br /><strong>Respiratory, thoracic and mediastinal disorders</strong><br />Common: yawning.<br /><strong>Gastrointestinal disorders</strong><br />Very common: nausea.<br />Common: constipation, diarrhoea, vomiting, dry mouth.<br />Very rare: gastrointestinal bleeding.<br />Unknown: Colitis microscopic.<br /><strong>Hepato-biliary disorders</strong><br />Rare: elevation of hepatic enzymes.<br />Very rare: hepatic events (such as hepatitis, sometimes associated with jaundice and/or liver&nbsp;<br />failure).<br />Elevation of hepatic enzymes has been reported. Post-marketing reports of hepatic events (such&nbsp;as hepatitis, sometimes associated with jaundice and/or liver failure) have also been received&nbsp;<br />very rarely. Discontinuation of Paroxat should be considered if there is prolonged elevation of&nbsp;liver function test results.<br /><strong>Skin and subcutaneous tissue disorders</strong><br />Common: sweating.<br />Uncommon: skin rashes, pruritus.<br />Very rare: severe cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson&nbsp;syndrome and toxic epidermal necrolysis), urticaria, photosensitivity reactions.<br /><strong>Renal and urinary disorders</strong><br />Uncommon: urinary retention, urinary incontinence.<br /><strong>Reproductive system and breast disorders</strong><br />Very common: sexual dysfunction.<br />Rare: hyperprolactinaemia/galactorrhoea.<br />Very rare: priapism.<br />Unknown: postpartum haemorrhage (* This event has been reported for the therapeutic class of&nbsp;SSRIs/SNRIs).<br /><strong>Musculoskeletal disorders</strong><br />Rare: arthralgia, myalgia.<br /><strong>General disorders and administration site conditions</strong><br />Common: asthenia, body weight gain.<br />Very rare: peripheral oedema.<br /><strong>Withdrawal symptoms seen on discontinuation of paroxetine treatment</strong><br />Common: dizziness, sensory disturbances, sleep disturbances, anxiety, headache<br />Uncommon: agitation, nausea, tremor, confusion, sweating, emotional instability, visual&nbsp;disturbances, palpitations, diarrhoea, irritability.</p><p><br />Discontinuation of Paroxat (particularly when abrupt) commonly leads to withdrawal symptoms.&nbsp;Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep&nbsp;disturbances (including intense dreams), agitation or anxiety, nausea, tremor, confusion,&nbsp;<br />sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual&nbsp;disturbances have been reported.Generally, these events are mild to moderate and self-limiting, however, in some patients they&nbsp;<br />may be severe and/or prolonged. It is therefore advised that when Paroxat treatment is no longer&nbsp;required, gradual discontinuation by dose tapering should be carried out (see section 4.2 and&nbsp;section 4.4).</p><p><br /><strong>Adverse events from paediatric clinical trials</strong><br />In short-term (up to 10-12 weeks) clinical trials in children and adolescents, the following&nbsp;adverse events were observed in paroxetine-treated patients at a frequency of at least 2% of&nbsp;patients and occurred at a rate at least twice that of placebo: increased suicidal-related behaviors(including suicide attempts and suicidal thoughts), self-harm behaviors and increased hostility.&nbsp;Suicidal thoughts and suicide attempts were mainly observed in clinical trials of adolescents with&nbsp;major depressive disorder. Increased hostility occurred particularly in children with obsessive&nbsp;compulsive disorder, and especially in younger children less than 12 years of age. Additional&nbsp;events that were more often seen in the paroxetine compared to placebo group were decreasedappetite, tremor, sweating, hyperkinesia, agitation, emotional lability (including crying and mood&nbsp;fluctuations).<br />In studies that used a tapering regimen, symptoms reported during the taper phase or upon&nbsp;discontinuation of paroxetine at a frequency of at least 2% of patients and occurred at a rate of at&nbsp;least twice that of placebo were emotional lability (including crying, mood fluctuations, selfharm, suicidal thoughts and attempted suicide), nervousness, dizziness, nausea and abdominalpain (see section 4.4)</p><p>&nbsp;</p><table border="1" align="left" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;To report any side effect(s):<br />For Saudi Arabia:</strong><br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662&nbsp;<br />SFDA Call Center: 19999&nbsp;<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br /><strong>For UAE:</strong><br />Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853<br />Tel: 80011111<br />Email: pv@moh.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai<br /><strong>For OMAN:</strong></p><p><strong>Department of Pharmacovigilance &amp; Drug Information<br />Directorate General of Pharmaceutical Affairs &amp; Drug Control<br />Ministry of Health, Sultanate of Oman<br />Phone Nos. 22357687 / 22357686<br />Fax: 22358489<br />Email: dg-padc@moh.gov.om<br />Website: www.moh.gov.om</strong></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Symptoms and signs</em></strong><br /><em>A wide margin of safety is evident from available overdose information on paroxetine.&nbsp;<br />Experience of paroxetine in overdose has indicated that, in addition to those symptoms&nbsp;<br />mentioned in section 4.8, vomiting, dilated pupils, fever, blood pressure changes, headache,&nbsp;<br />involuntary muscle contractions, agitation, anxiety and tachycardia have been reported. Patients&nbsp;<br />have generally recovered without serious sequelae even when doses of up to 2000 mg have been&nbsp;<br />taken alone. Events such as coma or ECG changes have occasionally been reported and very&nbsp;<br />rarely with a fatal outcome, but generally when paroxetine was taken in conjunction with other&nbsp;<br />psychotropic drugs, with or without alcohol.</em><br /><strong><em>Treatment</em></strong><br /><em>No specific antidote is known.<br />The treatment should consist of those general measures employed in the management of&nbsp;<br />overdose with any antidepressant. Where appropriate, the stomach should be emptied, either by&nbsp;<br />the induction of emesis, lavage or both.<br />Following evacuation, 20 to 30 g of activated charcoal may be administered every 4 to 6 h during&nbsp;<br />the first 24 h after ingestion. Supportive care with frequent monitoring of vital signs and careful&nbsp;<br />observation is indicated.</em></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antidepressants - selective serotonin reuptake inhibitors<br />ATC code: N06A B05<br /><strong>Mechanism of action</strong><br />Paroxetine is a potent and selective inhibitor of 5-hydroxytryptamine (5-HT, serotonin) uptake&nbsp;and its antidepressant action and effectiveness in the treatment of OCD, social anxiety&nbsp;disorder/social phobia, generalised anxiety disorder and panic disorder is thought to be related to&nbsp;its specific inhibition of 5-HT uptake in brain neurones.Paroxetine is chemically unrelated to the tricyclic, tetracyclic and other available antidepressants.Paroxetine has a low affinity for muscarinic cholinergic receptors and animal studies have&nbsp;indicated only weak anticholinergic properties. In accordance with this selective action, in vitro&nbsp;studies have indicated that, in contrast to tricyclic antidepressants, paroxetine has little affinity&nbsp;for alpha1, alpha2 or beta-adrenoceptors, dopamine (D2), 5-HT1-like, 5-HT2 and histamine (H1)&nbsp;receptors. This lack of interaction with post-synaptic receptors in vitro is substantiated by in vivo&nbsp;studies which demonstrate lack of CNS-depressant and hypotensive properties.<br /><strong>Pharmacodynamic effects</strong><br />Paroxetine does not impair psychomotor function and does not potentiate the depressants effects&nbsp;of ethanol.As with other selective 5-HT uptake inhibitors, paroxetine causes symptoms of excessive 5-HT&nbsp;receptor stimulation when administered to animals previously given monoamine oxidase (MAO)&nbsp;<br />inhibitors or tryptophan.Behavioural and EEG studies indicate that paroxetine is weakly activating at doses generally&nbsp;above those required to inhibit 5-HT uptake. The activating properties are not &quot;amphetaminelike&quot; in nature. Animal studies indicate that paroxetine is well tolerated by the cardiovascular&nbsp;<br />system. Paroxetine produces no clinically significant changes in blood pressure, heart rate and&nbsp;ECG after administration to healthy subjects.Studies indicate that, in contrast to antidepressants which inhibit the uptake of noradrenaline,&nbsp;paroxetine has a much reduced propensity to inhibit the antihypertensive effects of guanethidine.In the treatment of depressive disorders, paroxetine exhibits comparable efficacy to standard&nbsp;antidepressants. There is also some evidence that paroxetine may be of therapeutic value in&nbsp;<br />patients who have failed to respond to standard therapy.Morning dosing with paroxetine does not have any detrimental effect on either the quality or&nbsp;<br />duration of sleep. Moreover, patients are likely to experience improved sleep as they respond to&nbsp;paroxetine therapy.<br /><strong>Dose-response</strong><br />In the fixed dose studies there is a flat dose-response curve, providing no suggestion of&nbsp;advantage in terms of efficacy for using higher-than recommended doses. However, there are&nbsp;some clinical data suggesting that uptitrating the dose might be beneficial for some patients.<br /><strong>Long-term efficacy</strong><br />The long-term efficacy of paroxetine in depression has been demonstrated in a 52-week&nbsp;maintenance study with relapse prevention design: 12% of patients receiving paroxetine (20-40&nbsp;<br />mg daily) relapsed, versus 28% of patients on placebo.The long-term efficacy of paroxetine in treating obsessive compulsive disorder has been&nbsp;examined in three 24-week maintenance studies with relapse prevention design. One of the three&nbsp;<br />studies achieved a significant difference in the proportion of relapsers between paroxetine (38%)&nbsp;compared to placebo (59%).The long-term efficacy of paroxetine in treating panic disorder has been demonstrated in a 24&nbsp;week maintenance study with relapse prevention design: 5% of patients receiving paroxetine (10-40 mg daily) relapsed, versus 30% of patients on placebo. This was supported by a 36-week&nbsp;maintenance study.The long-term efficacy of paroxetine in treating social anxiety disorder and generalised anxiety&nbsp;<br />disorder has not been sufficiently demonstrated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption</em></strong><br /><em>Paroxetine is well absorbed after oral dosing and undergoes first-pass metabolism. Due to firstpass metabolism, the amount of paroxetine available to the systemic circulation is less than that&nbsp;absorbed from the gastrointestinal tract. Partial saturation of the first-pass effect and reduced&nbsp;<br />plasma clearance occur as the body burden increases with higher single doses or on multiple dosing. This results in disproportionate increases in plasma concentrations of paroxetine and&nbsp;hence pharmacokinetic parameters are not constant, resulting in non-linear pharmacokinetics.&nbsp;However, the non-linearity is generally small and is confined to those subjects who achieve low&nbsp;plasma levels at low doses.Steady-state systemic levels are attained by 7 to 14 days after starting treatment with immediate&nbsp;or controlled-release formulations and the pharmacokinetics do not appear to change during&nbsp;long-term therapy.<br /><strong>Distribution</strong><br />Paroxetine is extensively distributed into tissues and pharmacokinetic calculations indicate that&nbsp;only 1% of the paroxetine in the body resides in the plasma. Approximately 95% of the&nbsp;paroxetine present is protein-bound at therapeutic concentrations. No correlation has been found&nbsp;between paroxetine plasma concentrations and clinical effect (adverse experiences and efficacy).Transfer to human breast milk, and to the fetuses of laboratory animals, occurs in small amounts.<br /><strong>Metabolism</strong><br />The principal metabolites of paroxetine are polar and conjugated products of oxidation and&nbsp;methylation, which are readily cleared. In view of their relative lack of pharmacological activity,&nbsp;it is most unlikely that they contribute to the therapeutic effects of paroxetine.Metabolism does not compromise paroxetine&#39;s selective action on neuronal 5- HT uptake.<br /><strong>Elimination</strong><br />Urinary excretion of unchanged paroxetine is generally less than 2% of dose whilst that of&nbsp;metabolites is about 64% of dose. About 36% of the dose is excreted in the faeces, probably via&nbsp;the bile, of which unchanged paroxetine represents less than 1% of the dose. Thus paroxetine is&nbsp;<br />eliminated almost entirely by metabolism.Metabolite excretion is biphasic, being initially a result of first-pass metabolism and&nbsp;<br />subsequently controlled by systemic elimination of paroxetine.The elimination half-life is variable but is generally about 1 day.<br /><strong>Special patient populations</strong><br />Elderly and renal/hepatic impairment<br />Increased plasma concentrations of paroxetine occur in elderly subjects and in those subjects&nbsp;with severe renal impairment or in those with hepatic imppairment, but the range of plasma&nbsp;<br />concentrations overlaps with that of healthy adult subjects.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxicology studies have been conducted in rhesus monkeys and albino rats; in both, the&nbsp;metabolic pathway is similar to that described in humans. As expected with lipophilic amines,&nbsp;including tricyclic antidepressants, phospholipidosis was detected in rats. Phospholipidosis was&nbsp;not observed in primate studies of up to one-year&#39;s duration at doses that were 6 times higherthan the recommended range of clinical doses.<br /><strong>Carcinogesesis</strong><br />In two-year studies conducted in mice and rats, paroxetine had no tumorigenic effect.<br /><strong>Genotoxicity</strong><br />Genotoxicity was not observed in a battery of in vitro and in vivo tests.Reproduction toxicity studies in rats have shown that paroxetine affects male and female fertility.&nbsp;In rats, increased pup mortality and delayed ossification were observed. The latter effects were&nbsp;likely related to maternal toxicity and are not considered a direct effect on the fetus/neonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0"><tbody><tr><td><p>Dibasic Calcium Phosphate Dihydrate</p></td></tr><tr><td><p>Sodium Starch Glycolate</p></td></tr><tr><td><p>Polysorbate 80</p></td></tr><tr><td><p>Hydroxypropyl Cellulose (Klucel EF)</p></td></tr><tr><td><p>Magnesium Stearate</p></td></tr><tr><td><p>Titanium Dioxide</p></td></tr><tr><td><p>Purified Talc</p></td></tr><tr><td><p>Polyethylene Glycol MW 6000</p></td></tr><tr><td><p>Hydroxypropyl Methylcellulose</p></td></tr><tr><td><p>Purified Water</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48Months/4Years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transparent PVC/PVDC blister strips with aluminum foil lid 30 film-coated tablets/pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No Special Disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 SPIMACO
AlQassim pharmaceutical plant

Saudi Pharmaceutical Industries &

Medical Appliance Corporation

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2021.

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>